Organon Settles Remeron Antitrust Cases; Injunction Follows Bristol Model
Executive Summary
The proposed settlement of a patent listing case against Organon follows the model of the injunction negotiated by Bristol-Myers Squibb and the Federal Trade Commission a year ago
You may also be interested in...
Bristol Renounces Late-Listed Patents Under FTC Settlement
Bristol-Myers Squibb is surrendering its rights to a 30-month stay of approval in litigation over patents issued after an ANDA is on file at FDA
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials